Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes

Diabetes Care

Volumn 29, Issue 8, 2006, Pages 1812-1817

  Rave, Klaus ^a   Klein, Oliver ^a   Frick, Annke D ^b   Becker, Reinhard H A ^b  

^a Profil Institute for Metabolic Research   (Germany)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN GLULISINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SAFETY; FEMALE; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSULIN BLOOD LEVEL; INSULIN DEPENDENT DIABETES MELLITUS; MALE; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 1; DIET; FEMALE; HUMANS; INJECTIONS; INSULIN; MALE; MIDDLE AGED; RANDOM ALLOCATION;

EID: 33746602593     PISSN: 01495992     EISSN: 01495992     Source Type: Journal    
DOI: 10.2337/dc06-0383     Document Type: Article

References (33)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
2. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 352:854-865, 1998
3. Reichard P, Britz A, Cars I, Nilsson BY, Sobocinsky-Olsson B, Rosenqvist U: The Stockholm Diabetes Intervention Study (SDIS): 18 months' results. Acta Med Scand 224:115-122, 1988
4. American Diabetes Association: Clincial practice recommendations 2003: insulin administration. Diabetes Care 26 (Suppl. 1):S121-S124, 2003
5. Overmann H, Heinemann L: Injectionmeal interval: recommendations of diabetologists and how patients handle it. Diabetes Res Clin Pract 43:137-142, 1999
6. Valle D, Santoro D, Bates P, Scarpa L, the Italian Multicentre Lispro Study Group: Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with type 1 diabetes. Diabetes Nutr Metab 14:126-132, 2001
7. Becker RHA, Frick AD, Wessels DH, Scholtz HE: Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine: a novel, rapid-acting, human insulin analogue (Abstract). Diabetologia 46:A775, 2003
8. Frick AD, Becker RHA, Wessels DH, Scholtz HE: Pharmacokinetic and glucodynamic profiles of insulin glulisine: an evaluation following subcutaneous administration at various injection sites (Abstract). Diabetologia 46:A776, 2003
9. Garg SK, Ellis SL, Ulrich H: Insulin glulisine: a new rapid-acting insulin analogue for the treatment of diabetes. Expert Opin Pharmacother 6:643-651, 2005
10. Anderson JH Jr, Brunelle RL, Koivisto VA, Trautmann ME, Vignati L, DiMarchi R: Improved mealtime treatment of diabetes mellitus using an insulin analogue: Multicenter Insulin Lispro Study Group. Clin Ther 19:62-72, 1997
11. Heinemann L, Heise T, Jorgensen LN, Starke AA: Action profile of the rapid acting insulin analogue: human insulin B28Asp. Diabet Med 10:535-539, 1993
12. Torlone E, Pampanelli S, Lalli C, Del Sindaco P, Di Vincenzo A, Rambotti AM, Modarelli F, Epifano L, Kassi G, Perriello G, Brunetti P, Bolli G: Effects of the short-acting insulin analog [Lys(B28), Pro(B29)] on postprandial blood glucose control in IDDM. Diabetes Care 19:945-952, 1996
13. Pampanelli S, Fanelli C, Lalli C, Ciofetta M, Sindaco PD, Lepore M, Modarelli F, Rambotti AM, Epifano L, Di Vincenzo A, Bartocci L, Annibale B, Brunetti P, Bolli GB: Long-term intensive insulin therapy in IDDM: effects on HbA1c, risk for severe and mild hypoglycaemia, status of counterregulation and awareness of hypoglycaemia. Diabetologia 39:677-686, 1996
14. Strachan MW, Frier BM: Optimal time of administration of insulin lispro: importance of meal composition. Diabetes Care 21:26-31, 1998
15. Brange J, Volund A: Insulin analogs with improved pharmacokinetic profiles. Adv Drug Deliv Rev 35:307-335, 1999
16. Home PD, Lindholm A, Hylleberg B, Round P: Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients: UK Insulin Aspart Study Group. Diabetes Care 21:1904-1909, 1998
17. Brunner GA, Hirschberger S, Sendlhofer G, Wutte A, Ellmerer M, Balent B, Schaupp L, Krejs GJ, Pieber TR: Postprandial administration of the insulin analogue insulin aspart in patients with type 1 diabetes mellitus. Diabet Med 17:371-375, 2000
18. Schernthaner G, Wein W, Sandholzer K, Equiluz-Bruck S, Bates PC, Birkett MA: Postprandial insulin lispro. A new therapeutic option for type 1 diabetic patients. Diabetes Care 21:570-573, 1998
19. Siebenhofer A, Plank J, Berghold A, Narath M, Gfrerer R, Pieber TR: Short acting insulin analogues versus regular human insulin in patients with diabetes mellitus. Cochrane Database Syst Rev 4:CD003287, 2004
20. Hirsch IB, Brownlee M: Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications 19:178-181, 2005
21. Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechini MG, Bartocci L, Brunetti P, Bolli GB: Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22:468-477, 1999
22. Garg SK, Rosenstock J, Ways K: Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine. Endocr Pract 11:11-17, 2005
23. Schernthaner G, Wein W, Shnawa N, Bates PC, Birkett MA: Preprandial vs. postprandial insulin lispro-a comparative crossover trial in patients with type 1 diabetes. Diabet Med 21:279-284, 2004
24. Heise T, Heinemann L: Rapid and long-acting analogues as an approach to improve insulin therapy: an evidence-based medicine assessment. Curr Pharm Des 7:1303-1325, 2001
25. Danne T, Becker RH, Heise T, Bittner C, Frick AD, Rave K: Pharmacokinetics and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 28:2100-2105, 2005
26. Heinemann L, Starke AA, Hohmann A, Berger M: Timing between the subcutaneous administration of insulin and consumption of a carbohydrate rich meal. Horm Metab Res Suppl 26:137-139, 1992
27. 1c. Diabetes Care 26: 881-885, 2003
28. Home P: Contributions of basal and postprandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 21:989-998, 2005
29. Landgraf R: The relationship of postprandial glucose to HbA1c. Diabetes Metab Res Rev 20 (Suppl. 2):S9-S12, 2004
30. Bonora E: Postprandial blood glucose as a risk factor for cardiovascular disease in type II diabetes: the epidemiological evidence. Diabetologia 44:2107-2114, 2001
31. Ceriello A: Postprandial hyperglycemia and diabetes complications: is it time to treat? Diabetes 54:1-7, 2005
32. Heine RJ, Dekker JM: Beyond postprandial hyperglycemia: metabolic factors associated with cardiovascular disease. Diabetologia 45:461-475, 2002
33. Gerich JE: The importance of tight glycemic control. Am J Med 118(Suppl. 9A):7S-11S, 2005